X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Bemdaneprocel (BRT-DA01) is an investigational allogeneic stem cell derived cell therapy designed to replace the dopamine producing neurons that are lost in Parkinson’s disease.
Lead Product(s): Bemdaneprocel
Therapeutic Area: Neurology Product Name: BRT-DA01
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Details:
Under the agreement, BlueRock exercised its option to exclusively license OpCT-001, an induced pluripotent stem cell (iPSC) derived cell therapy candidate for the treatment of primary photoreceptor diseases.
Lead Product(s): OpCT-001
Therapeutic Area: Genetic Disease Product Name: OpCT-001
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Fujifilm Cellular Dynamics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 23, 2024
Details:
BRT-DA01 (bemdaneprocel) is an investigational therapy comprised of dopamine producing neurons derived from pluripotent stem cells, is surgically implanted into the brain of a person with Parkinson’s disease.
Lead Product(s): Bemdaneprocel
Therapeutic Area: Neurology Product Name: BRT-DA01
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Details:
Under the agreement, bit.bio will use its machine learning powered discovery platform to identify transcription factor combinations for reprogramming iPSCs into Tregs, for the discovery and manufacture of iPSC-derived regulatory T cells for use in creating therapeutics.
Lead Product(s): iPSC-derived T-cell Based Therapy
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Recipient: Bit Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 03, 2023
Details:
BRT-DA01 (bemdaneprocel), is an investigational therapy comprised of dopamine producing neurons derived from pluripotent stem cells, is surgically implanted into the brain of a person with Parkinson’s disease.
Lead Product(s): Bemdaneprocel
Therapeutic Area: Neurology Product Name: BRT-DA01
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Recipient: Bayer AG
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2023
Details:
The agreement has an option to negotiate for a non-exclusive world-wide license to BioCardia biotherapeutic delivery product candidates for certain cell types for cardiac indications and is time limited.
Lead Product(s): Undisclosed
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Recipient: BioCardia
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 24, 2022
Details:
The primary objective of the Ph1 trial is to assess the safety and tolerability of BRT-DA01 transplantation at one-year post-transplant. The secondary objectives are to assess the evidence of transplanted cell survival and motor effects at one- and two-years post-transplant.
Lead Product(s): DA01
Therapeutic Area: Neurology Product Name: BRT-DA01
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2022
Details:
The purpose of the Ph1 clinical trial is to evaluate the safety, tolerability and preliminary efficacy of DA01. DA01 is being clinically evaluated in a subset of patients with advanced Parkinson’s disease, where regular medications are no longer fully effective.
Lead Product(s): DA01
Therapeutic Area: Neurology Product Name: DA01
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2022
Details:
The primary objective of the Ph1 trial is to assess the safety and tolerability of DA01 cell transplantation at one-year post-transplant. The secondary objectives, are to assess the evidence of transplanted cell survival and motor effects at one and two-years post-transplant.
Lead Product(s): DA01
Therapeutic Area: Neurology Product Name: DA01
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2022
Details:
The primary objective of the Ph1 study is to assess the safety and tolerability of DA01 cell transplantation at one-year post-transplant.
Lead Product(s): DA01
Therapeutic Area: Neurology Product Name: DA01
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
